- Covers Methods in Using the Celution®
System for Cell-Enhanced Reconstruction -
Cytori Therapeutics (NASDAQ: CYTX) today received U.S. Patent No.
7,429,488 (the ‘488 patent), which broadly
protects the Company’s Celution®
System-based methods of generating adipose tissue-derived stem and
regenerative cell-enhanced fat grafts. Cell-enhanced fat grafts may be
used in a variety of cosmetic and reconstructive surgery applications,
including breast reconstruction following partial mastectomy, breast
implant salvage, as well as facial and other cosmetic applications. The
Celution 800/CRS System is currently available for sale in Europe and
parts of Asia.
Receipt of the ‘488 patent, which runs until
at least January 2024, is important to Cytori because it further
strengthens the Celution System’s competitive
position within the cosmetic and reconstructive surgery market. Part of
Cytori’s strategy to create greater
barriers-to-entry is to protect distinct applications of the Celution
System. This allows Cytori to build additional layers of protection
around U.S. Patent No. 7,390,484, which was recently issued to Cytori
and covers the Celution System’s core
technology. Additional patents have been filed around other Celution
System applications, including cell banking, cardiovascular disease,
spine and orthopedic repair, among others.
This patent broadly protects Cytori’s Celution
800/CRS System, which automates the method of creating a cell-enhanced
fat graft. First, the Celution 800/CRS System processes stem and
regenerative cells from a small amount of adipose tissue. Next, the
Celution 800/CRS System mixes these cells with liposuctioned fat tissue.
This forms the cell-enhanced fat graft, which may be used as a natural
filler to reconstruct soft tissue defects.
Cytori’s intellectual property portfolio
related to the devices, methods and uses of adipose-derived stem and
regenerative cells includes eight U.S. and international patents and
over 120 applications pending worldwide. Combined with Cytori’s
proprietary know-how, exclusive supply agreements, and instrumentation,
greater barriers-to-entry are being created to offer what the Company
believes is the only safe, high-quality and effective adipose tissue
processing device.
About Cytori
Cytori’s (NASDAQ: CYTX) goal is to be the
global leader in regenerative medicine.
